文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee.

作者信息

Birtcher Kim K, Allen Larry A, Anderson Jeffrey L, Bonaca Marc P, Gluckman Ty J, Hussain Aliza, Kosiborod Mikhail, Mehta Laxmi S, Virani Salim S

出版信息

J Am Coll Cardiol. 2023 Jan 24;81(3):292-317. doi: 10.1016/j.jacc.2022.08.754. Epub 2022 Oct 25.

DOI:10.1016/j.jacc.2022.08.754
PMID:36307329
Abstract
摘要

相似文献

[1]
2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee.

J Am Coll Cardiol. 2023-1-24

[2]
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.

J Am Coll Cardiol. 2023-5-9

[3]
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.

J Am Coll Cardiol. 2020-9-1

[4]
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.

J Am Coll Cardiol. 2022-10-4

[5]
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.

J Am Coll Cardiol. 2023-3-21

[6]
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.

J Am Coll Cardiol. 2024-4-16

[7]
2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee.

J Am Coll Cardiol. 2021-2-9

[8]
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

J Am Coll Cardiol. 2016-7-5

[9]
New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia.

Cardiol Clin. 2015-5

[10]
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

J Am Coll Cardiol. 2017-9-5

引用本文的文献

[1]
Lambl's Excrescences and Cardiac Papillary Fibroelastoma, an Unusual Cause of Embolic Strokes: Extended Data From a Single Center Case Series.

Cureus. 2025-7-31

[2]
Effectiveness of digital healthcare to improve clinical outcomes in discharged patients with coronary artery disease.

NPJ Digit Med. 2025-7-23

[3]
Multimorbidity in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

JACC Adv. 2025-7-22

[4]
Determinants of polypharmacy among ambulatory cardiovascular disease patients in Iluababora and Buno Bedele Zones, Ethiopia: prospective observational study.

BMC Cardiovasc Disord. 2025-7-4

[5]
Relationship Between Timing of PCSK9 Inhibitor Monoclonal Antibody Initiation and Clinical Outcomes in Patients with Prior Cardiovascular Events.

Ther Clin Risk Manag. 2025-5-21

[6]
Balancing polypharmacy and comorbidity management: cardiovascular health.

Curr Opin HIV AIDS. 2025-7-1

[7]
Exploring Erythrina flavonoids as potential SARS-CoV-2 RdRp inhibitors through virtual screening, in silico ADMET evaluation, and molecular dynamics simulation studies.

Sci Rep. 2025-4-24

[8]
Effects of sodium tanshinone IIA sulfonate injection on pro-inflammatory cytokines, adhesion molecules and chemokines in Chinese patients with atherosclerosis and atherosclerotic cardiovascular disease: a meta-analysis of randomized controlled trials.

Front Cardiovasc Med. 2025-2-13

[9]
Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology.

J Am Coll Cardiol. 2025-3-18

[10]
Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.

Int J Mol Sci. 2025-1-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索